{"filing":{"accession_number":"0001193125-26-276093","cik":"0001829802","ticker":"SNSE","company_name":"Faeth Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"d82589d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526276093/d82589d8k.htm"},"events":[{"id":11985,"run_id":10547,"accession_number":"0001193125-26-276093","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Faeth Therapeutics entered into an at-the-market (ATM) offering agreement with TD Securities on June 18, 2026, authorizing the sale of up to $150 million in common stock shares, representing a classic dilutive equity issuance that signals potential capital needs and future shareholder dilution.","company_name":"Faeth Therapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8714,"accession_number":"0001193125-26-276093","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Faeth Therapeutics entered into an at-the-market (ATM) offering agreement with TD Securities on June 18, 2026, authorizing the sale of up to $150 million in common stock shares. ATM offerings are a classic form of dilutive equity issuance that allow companies to raise capital opportunistically while diluting existing shareholders. This is material to investors as it signals potential capital needs and future share dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:14:09.348800+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":11986,"run_id":10547,"accession_number":"0001193125-26-276093","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.72,"summary":"Automatic conversion of 24,435.594 shares of Series B Non-Voting Convertible Preferred Stock into 24,435,594 shares of Common Stock materially increased the outstanding share count to 25,778,754 shares, resulting in significant dilution to existing shareholders' ownership percentages and earnings per share.","company_name":"Faeth Therapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8715,"accession_number":"0001193125-26-276093","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The automatic conversion of 24,435.594 shares of Series B Non-Voting Convertible Preferred Stock into 24,435,594 shares of Common Stock represents a significant dilutive issuance event that materially increases the outstanding share count from an undisclosed prior level to 25,778,754 shares. While this appears to be a contractual conversion rather than a new equity issuance, the substantial increase in common shares outstanding and the resulting dilution to existing shareholders would affect a reasonable investor's assessment of ownership percentages and earnings per share. The event does not fit cleanly into dilutive_issuance (which typically covers new private placements or convertible offerings) but is material enough to warrant disclosure beyond routine administrative treatment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:14:09.348800+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8714,"accession_number":"0001193125-26-276093","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Faeth Therapeutics entered into an at-the-market (ATM) offering agreement with TD Securities on June 18, 2026, authorizing the sale of up to $150 million in common stock shares. ATM offerings are a classic form of dilutive equity issuance that allow companies to raise capital opportunistically while diluting existing shareholders. This is material to investors as it signals potential capital needs and future share dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:14:09.348800+00:00","company_name":"Faeth Therapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-18"},{"id":8715,"accession_number":"0001193125-26-276093","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The automatic conversion of 24,435.594 shares of Series B Non-Voting Convertible Preferred Stock into 24,435,594 shares of Common Stock represents a significant dilutive issuance event that materially increases the outstanding share count from an undisclosed prior level to 25,778,754 shares. While this appears to be a contractual conversion rather than a new equity issuance, the substantial increase in common shares outstanding and the resulting dilution to existing shareholders would affect a reasonable investor's assessment of ownership percentages and earnings per share. The event does not fit cleanly into dilutive_issuance (which typically covers new private placements or convertible offerings) but is material enough to warrant disclosure beyond routine administrative treatment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:14:09.348800+00:00","company_name":"Faeth Therapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-18"}]}